APC inact mut: Gene Variant Detail - Cancer Knowledgebase (CKB)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Showing 1 to 32 of 32 entries

Filter rows:

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
APC inact mut	prostate cancer	decreased response	Abiraterone	Clinical Study	Actionable	In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) following Zytiga (abiraterone) or Xtandi (enzalutamide) treatment compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).	31176623
APC inact mut	prostate cancer	decreased response	Enzalutamide	Clinical Study	Actionable	In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) following Zytiga (abiraterone) or Xtandi (enzalutamide) treatment compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).	31176623
APC inact mut	desmoid tumor	predicted - sensitive	BMS-906024	Case Reports/Case Series	Actionable	In a clinical case study, BMS-906024 treatment resulted in a partial response that lasted for at least 2.6 years in a patient with a desmoid tumor harboring an inactivating APC mutation (PMID: 34590610).	34590610
APC inact mut	desmoid tumor	predicted - sensitive	Nirogacestat	Case Reports/Case Series	Actionable	In a clinical case study, Ogsiveo (nirogacestat) resulted in stable disease lasting 9 months in a patient with a patient with a desmoid tumor harboring an inactivating APC mutation (PMID: 32762028).	32762028
APC inact mut	colorectal cancer	sensitive	Celecoxib + Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).	17909047
APC inact mut	colorectal cancer	sensitive	Erlotinib + Ibuprofen	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).	17909047
APC inact mut	colorectal cancer	sensitive	NC043	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).	21321609
APC inact mut	colon cancer	sensitive	iCRT-14	Preclinical - Cell line xenograft	Actionable	In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).	21393571
APC inact mut	colon cancer	sensitive	G007-LK	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).	23539443
APC inact mut	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).	27798265
APC inact mut	colon cancer	sensitive	Sirolimus	Preclinical	Actionable	In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).	18768809 20080688
APC inact mut	colon cancer	sensitive	Vinorelbine	Preclinical	Actionable	In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).	22399804
APC inact mut	colon cancer	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).	20811697
APC inact mut	colorectal cancer	sensitive	Celecoxib	Preclinical	Actionable	In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).	17909047
APC inact mut	colorectal cancer	sensitive	Sulindac	Preclinical	Actionable	In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).	19755659
APC inact mut	colorectal cancer	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).	20473900
APC inact mut	colon cancer	sensitive	CGP049090	Preclinical	Actionable	In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).	14749129
APC inact mut	colon cancer	sensitive	ICG-001	Preclinical	Actionable	In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234).	15314234
APC inact mut	colon cancer	sensitive	MF tricyclic	Preclinical	Actionable	In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).	23843721
APC inact mut	colon cancer	sensitive	PKF115-584	Preclinical	Actionable	In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).	14749129
APC inact mut	colon cancer	sensitive	StAx-35	Preclinical	Actionable	In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).	23071338
APC inact mut	colorectal cancer	sensitive	XAV939	Preclinical	Actionable	In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).	19759537
APC inact mut	colon carcinoma	sensitive	FH535	Preclinical	Actionable	In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139).	18347139
APC inact mut	colorectal cancer	sensitive	PKF118-310	Preclinical	Actionable	In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).	14749129
APC inact mut	colorectal cancer	sensitive	CCT036477	Preclinical	Actionable	In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).	20610623
APC inact mut	colorectal cancer	sensitive	CCT070535	Preclinical	Actionable	In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).	20610623
APC inact mut	colorectal cancer	sensitive	CCT031374	Preclinical	Actionable	In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).	20610623
APC inact mut	colon cancer	sensitive	iCRT-3	Preclinical	Actionable	In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).	21393571
APC inact mut	colon cancer	sensitive	JW55	Preclinical	Actionable	In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).	22440753
APC inact mut	colorectal cancer	sensitive	Pyrvinium	Preclinical	Actionable	In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).	20890287
APC inact mut	colon cancer	sensitive	iCRT-5	Preclinical	Actionable	In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).	21393571
APC inact mut	colorectal cancer	sensitive	Niclosamide	Preclinical	Actionable	In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).	21531761

Showing 1 to 32 of 32 entries

Filter rows:

Gene	APC
Variant	inact mut
Impact List	unknown
Protein Effect	loss of function
Gene Variant Descriptions	APC inact mut indicates that this variant results in a loss of function of the Apc protein. However, the specific amino acid change has not been identified.
Associated Drug Resistance
Category Variants Paths	APC mutant APC inact mut

APC inact mut
Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting

APC inact mutGene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting

APC inact mut
Gene Variant Detail